<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093742</url>
  </required_header>
  <id_info>
    <org_study_id>HM-GHA-101</org_study_id>
    <nct_id>NCT01093742</nct_id>
  </id_info>
  <brief_title>A Study of HM10560A in Healthy Male Subject</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM10560A After S.C. Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Study Design

             -  Randomized, Double-blind, Placebo-controlled, escalating single-dose design.

             -  Four ascending dose cohorts.

             -  In each cohort, subjects will be randomized to receive a single dose of HM10560A or
                placebo (negative control).

        -  Objectives

             -  The primary objective of the study is to assess the safety and tolerability of
                single escalating subcutaneous doses of HM10560A in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of the study are as follows:

        -  To assess the pharmacokinetics(PK) and pharmacodynamics(PD) of a single subcutaneous
           dose of HM10560A.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1, 2, 3, 5, 7, 11, 15, 22, 29 day after administration</time_frame>
    <description>Investigate Safety of HM10560A:
Physical examination, Laboratory test, ECG, Vital sign, Adverse event, Local tolerability</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM10560A 0.089 mg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM10560A 0.179 mg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM10560A 0.357 mg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM10560A 0.714 mg/kg or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10560A</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers, age range 20 to 54 years are informed of the investigational
             nature of this study and voluntarily agrees to participate in this study

          2. Body mass index of ≥19 and ≤26 Subject

          3. Medically healthy with no clinically significant screening results through Physical
             examination, 12 lead ECG, Laboratory test

          4. Able to participate in all procedure

          5. SBP 90-140 mmHg, DBP 60-90 mmHg, Pulse rate 50-90 times/min

          6. AST, ALT &lt;1.5 X UNL, CPK &lt; 2 X UNL

          7. Able to abstain from alcohol and smoke during study period

          8. Consented to contraception until 2 month after end of the study

        Exclusion Criteria:

          1. Acute infection history within 14 days

          2. Prior exposure or hypersensitivity to recombinant human growth hormone

          3. Positive findings on HBsAg, Anti-HAV IgM, anti-HCV, HIV Ag, HIV Ab and syphilis high
             quality regain test

          4. History of significant gastrointestinal, cardiac, pulmonary, hepato- and nephro-
             disease

          5. psychiatric disorder, malignancy tumor, hormonal disorder, diabetes mellitus and
             hypertension or history of immunosuppressant treatment

          6. Caffeine, alcohol and smoke abuse

          7. History of hemophilia or anticoagulant treatment

          8. Revulsion and/or panic about syringe needle and hypersensitivity to subcutaneously
             administration

          9. History drug abuse or positive testing for amphetamine, barbiturate, cocaine, opiates,
             benzodiazepines

         10. Blood donation or significant blood loss within 60 days prior to Day 1. Plasma
             donation or transfusion within 30 days prior to Day 1.

         11. Receipt of another investigational medication within 60 days prior to Day 1

         12. Use of any herbal products within 30 days or prescription medication within 14 days or
             over-the-counter medication within 7 days prior to the Day 1.

         13. Subjects who are unlikely to comply with the protocol requirements, instructions and
             study related restrictions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jahon Kang</last_name>
    <role>Study Director</role>
    <affiliation>Hanmi pharma.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

